Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
20–64
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Overtly healthy Japanese or Caucasian
Body mass index (BMI) 18.0 - 32.0 kilograms per square meter (kg/m²)
You may not be if
Have participated, within the last 30 days, in a clinical study involving an investigational product (IP). If the previous IP has a long half-life, 5 half-lives or 30 days (whichever is longer) should have passed
Have had symptomatic herpes zoster within 3 months of screening
Show evidence of active or latent tuberculosis (TB)
Have known hypogammaglobulinemia or a screening serum immunoglobulin (Ig) G \<565 milligrams per deciliter (mg/dL)
Have received live or attenuated vaccine(s) within 1 month of screening, or intend to during the study
Are immunocompromised
Have received treatment with biologic agents (such as monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing. Participants with any prior exposure to ixekizumab, tabalumab or other biologic agents directly targeting Interleukin 17 (IL-17) and/or B cells (e.g., rituximab, belimumab, etc.) are excluded
Clareo Health | A Study of LY3090106 in Japanese and Caucasian Healthy Participants
